Although cell-specificity and off-target effects should be considered, CRISPR strategies may offer a means of excising or modifying pathogenic microglia AD risk genes, such CD33, APOE, and TREM2. Another notable innovation has been the development of CAR (chimeric antigen receptor)-T cell therapy. This evidence concerns the gene CD33 and Alzheimer disease.